Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the ...

Fujirebio collaborates with Stanford Medicine to advance research and innovation in the field of infectious disease testing: Tokyo, Japan Saturday, June 7, 2025, 13:00 Hrs [IST] F ...

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary ...

Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years' accumulated experience in the ...

Fujirebio, a leading innovator in in-vitro diagnostics, today announced a collaboration with Stanford Medicine (Location: Palo Alto, California, USA) to advance research and innovation in the ...

GENT, Belgium & MALVERN, Pa. & TOKYO — H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated ...

The U.S. Food and Drug Administration has approved the marketing of a new tool to that can test a person’s blood to diagnose ...

H.U. Group Holdings Inc. and its subsidiary Fujirebio have announced the launch of the Lumipulse G sTREM2 assay, a ...

As an Alzheimer’s caregiver writes, a biomarker test was recently approved by the FDA and can lead to earlier treatment.

The Food and Drug Administration (FDA) cleared the first blood test recently to help diagnose Alzheimer's disease.